How Does MTAP Loss Reshape PRMT5 Dependency?

MTAP loss disrupts the methionine salvage pathway, resulting in the accumulation of 5′-methylthioadenosine (MTA) and partial inhibition of PRMT5 activity. Cancer cells consequently enter a state with limited PRMT5 functional reserve and develop greater dependence on residual PRMT5 activity and SAM supply, making MTAP loss an exploitable metabolic vulnerability in cancer.

Keywords: MTAP; PRMT5; MTA; MAT2A; SAM; SDMA; synthetic lethality; tumor metabolism

1 Metabolic Basis of MTAP Loss

1.1 MTAP and the Methionine Salvage Pathway

MTAP (methylthioadenosine phosphorylase) participates in the methionine salvage pathway by catalyzing the phosphorolysis of 5′-methylthioadenosine (MTA), a by-product of polyamine synthesis, into adenine and 5-methylthioribose-1-phosphate. The latter is further metabolized to regenerate methionine. Loss of MTAP impairs MTA clearance and reduces the efficiency of methionine salvage, allowing an intermediate originally generated during polyamine metabolism to accumulate and alter the cellular methylation environment.

1.2 Co-Deletion of MTAP and CDKN2A

MTAP is located in the chromosome 9p21 region adjacent to the tumor suppressor gene CDKN2A. When tumors acquire homozygous deletion of CDKN2A, the deleted region frequently extends into MTAP, resulting in co-deletion of both genes. This alteration occurs in pancreatic cancer, non-small cell lung cancer, mesothelioma, glioblastoma, urothelial carcinoma, and other tumor types. CDKN2A loss primarily disrupts cell-cycle regulatory pathways such as the p16INK4A–CDK4/6–RB axis, whereas MTAP loss additionally causes abnormal MTA metabolism. Homozygous MTAP deletion and loss of MTAP protein have therefore become important patient-stratification markers in PRMT5- and MAT2A-targeted research.

1.3 MTA Accumulation Alters the Methylation Environment

S-adenosylmethionine (SAM) is the principal cellular methyl donor and supplies methyl groups for methylation reactions involving DNA, RNA, histones, and other proteins. MTA is structurally related to SAM and can influence several SAM-dependent methyltransferases, with protein arginine methyltransferase 5 (PRMT5) being particularly sensitive to MTA. MTAP loss therefore not only changes metabolite levels but also directly affects PRMT5-mediated protein arginine methylation.

2 How MTAP Loss Creates PRMT5 Dependency

2.1 PRMT5 and Symmetric Arginine Dimethylation

PRMT5 (protein arginine methyltransferase 5) is a type II protein arginine methyltransferase that commonly forms a catalytic complex with WDR77/MEP50 and other proteins. Using SAM as its methyl donor, PRMT5 catalyzes arginine monomethylation and symmetric dimethylation, generating symmetric dimethylarginine (SDMA). Its substrates include spliceosome-associated proteins such as SmB/B′, SmD1, and SmD3, as well as histones and proteins involved in DNA replication, DNA damage responses, and cell-cycle regulation. PRMT5 therefore serves as an important regulatory node connecting RNA processing, gene expression, and cell proliferation.

2.2 MTA Places PRMT5 in a Partially Inhibited State

(1) MTA Restricts PRMT5 Catalytic Activity

Elevated MTA following MTAP loss can bind to PRMT5 and restrict SAM-dependent methyltransferase reactions, reducing PRMT5 catalytic outputs such as SDMA. PRMT5 does not completely lose function under these conditions but remains partially inhibited by endogenous MTA, reducing the functional reserve available to tolerate further PRMT5 suppression.

(2) The Tumor Microenvironment Influences MTA Levels

MTAP loss does not necessarily produce identical MTA accumulation in all tumor tissues. MTA released by MTAP-deficient tumor cells may be metabolized by surrounding MTAP-intact fibroblasts, immune cells, and other stromal cells. Actual intratumoral MTA levels are consequently influenced by tumor purity and stromal composition, meaning that MTAP genotype and the MTA metabolic phenotype are not always completely equivalent.

2.3 Residual PRMT5 Activity Becomes a Survival Dependency

Although PRMT5 is partially inhibited in MTAP-deficient cancer cells, residual activity remains necessary for spliceosome assembly, RNA processing, and cell survival. Further genetic depletion or pharmacological inhibition of PRMT5 can more readily push these cells below the functional threshold required to maintain essential cellular processes, whereas MTAP-intact cells retain a relatively greater PRMT5 functional reserve. MTA accumulation caused by MTAP loss therefore places cancer cells in a state of increased sensitivity to further suppression of residual PRMT5 activity.

3 Functional Basis of PRMT5 Dependency

3.1 RNA Splicing

PRMT5 symmetrically dimethylates Sm proteins such as SmB/B′, SmD1, and SmD3, promoting their interaction with the SMN complex and supporting small nuclear ribonucleoprotein (snRNP) assembly. Further inhibition of PRMT5 impairs spliceosome function, causing intron retention, abnormal exon selection, and other pre-mRNA splicing defects. These alterations affect transcripts involved in cell-cycle regulation, DNA repair, and cell survival. Because MTAP-deficient cells already have restricted PRMT5 activity, they are more sensitive to additional disruption of RNA processing.

3.2 Cell-Cycle Regulation and DNA Damage Responses

PRMT5 participates in cell-cycle progression, DNA replication, and the expression and functional maintenance of DNA damage-response proteins. Abnormal RNA splicing caused by reduced PRMT5 activity can further disrupt cell-cycle regulators and DNA repair factors, leading to slower proliferation, cell-cycle arrest, replication stress, and increased DNA damage. MAT2A inhibition can similarly reduce PRMT5-associated methylation and RNA splicing by limiting SAM availability, extending this vulnerability from PRMT5 itself to upstream methyl-donor metabolism.

4 Major Strategies for Targeting MTAP–PRMT5 Dependency

4.1 MTA-Cooperative PRMT5 Inhibition

MTA-cooperative PRMT5 inhibitors exploit the MTA-rich environment of MTAP-deficient cells and preferentially target the PRMT5–MTA complex. In cancer cells with MTA accumulation, these compounds more effectively reduce PRMT5 catalytic activity and SDMA levels, while exerting comparatively weaker effects in MTAP-intact cells. MRTX1719, AMG 193, and Vopimetostat use this mechanism. Their central advantage is not simply stronger PRMT5 inhibition but the ability to exploit metabolic differences in MTA between tumors and normal tissues to establish selectivity.

4.2 MAT2A Inhibition

MAT2A (methionine adenosyltransferase 2A) catalyzes the production of SAM from methionine and ATP and is an important metabolic enzyme that maintains SAM supply in proliferating cells. Because PRMT5 is already partially restricted by MTA in MTAP-deficient cells, further inhibition of MAT2A reduces SAM availability and suppresses PRMT5 catalytic activity from the methyl-donor side. MAT2A inhibitors such as IDE397 and AG-270 therefore represent another strategy for targeting MTAP-deficient tumors in parallel with MTA-cooperative PRMT5 inhibition.

4.3 Dual Intervention in PRMT5 and MAT2A

MAT2A generates SAM, whereas PRMT5 uses SAM to catalyze arginine methylation, placing the two proteins at different positions within the same metabolic–methylation axis. MAT2A inhibition restricts methyl-donor availability, while MTA-cooperative PRMT5 inhibition acts directly at the catalytic execution step. Combined intervention can further reduce SDMA and PRMT5-dependent RNA processing and may amplify the methylation vulnerability created by MTAP loss.

4.4 Non-MTA-Selective PRMT5 Inhibition

PRMT5 inhibitors such as EPZ015866 and Pemrametostat directly reduce PRMT5 catalytic activity and SDMA modification and are used to investigate the roles of PRMT5 in RNA splicing, cell-cycle regulation, and tumor cell survival. These compounds do not specifically exploit the MTA-rich environment created by MTAP loss and also inhibit PRMT5 in MTAP-intact cells, making them more suitable as tools for PRMT5 functional validation and pharmacological mechanism studies.

5 Research Progress in Targeting MTAP-Deficient Tumors

5.1 MRTX1719

(1) MTA-Cooperative PRMT5 Inhibition

MRTX1719 is a representative MTA-cooperative PRMT5 inhibitor that preferentially binds PRMT5 when it is occupied by MTA. In MTAP-deficient tumor models, MRTX1719 substantially reduces SDMA levels, alters PRMT5-dependent RNA splicing, and inhibits tumor cell proliferation while showing lower activity against MTAP-intact cells.

(2) Clinical Studies

MRTX1719 has entered human studies in advanced solid tumors with homozygous MTAP deletion. Early clinical studies have reported objective responses in patients with different MTAP-deficient tumors, including mesothelioma, non-small cell lung cancer, melanoma, and gallbladder cancer, providing clinical validation of metabolically selective MTA-cooperative PRMT5 inhibition.

5.2 AMG 193

(1) Targeting the PRMT5–MTA Complex

AMG 193 is also an MTA-cooperative PRMT5 inhibitor that exploits the MTA-rich environment created by MTAP loss to enhance tumor selectivity. In preclinical studies, AMG 193 reduced SDMA levels, induced PRMT5-associated splicing abnormalities, and produced antitumor effects in multiple MTAP-deficient solid tumor models.

(2) Early Clinical Studies

Early human studies of AMG 193 demonstrated pharmacodynamic inhibition of PRMT5 in multiple MTAP-deficient solid tumors, with objective responses observed in some patients, providing clinical validation of MTA-cooperative PRMT5 inhibition. However, further clinical development of AMG 193 was discontinued in April 2026, and the compound is therefore better regarded as a representative example of clinical validation of this mechanism rather than an actively advancing program.

5.3 Vopimetostat

(1) MTAP-Selective PRMT5 Inhibition

Vopimetostat (TNG462) is an MTA-cooperative PRMT5 inhibitor that uses MTA accumulation in MTAP-deficient tumors to selectively reduce PRMT5 activity and SDMA output. Its development primarily targets pancreatic cancer, non-small cell lung cancer, and other MTAP-deficient solid tumors.

(2) Combination Treatment Studies

In addition to monotherapy studies, Vopimetostat has been evaluated in combination with RAS pathway inhibitors. RAS-driven signaling sustains the proliferation and survival of certain tumors, whereas PRMT5 inhibition targets the metabolic vulnerability created by MTAP loss. Dual intervention in oncogenic signaling and metabolic dependency has therefore become an important direction in the development of Vopimetostat.

5.4 IDE397

(1) MAT2A Inhibition

IDE397 inhibits MAT2A and reduces SAM production, further limiting methyl-donor availability for PRMT5 already restricted by MTA. Unlike direct PRMT5 inhibitors, IDE397 exploits MTAP-associated metabolic selectivity from the upstream SAM-supply step and influences PRMT5-dependent SDMA and RNA splicing.

(2) Studies in MTAP-Deficient Solid Tumors

IDE397 has entered clinical studies in MTAP-deficient solid tumors, including non-small cell lung cancer and urothelial carcinoma, and is being further evaluated in combination with other targeted agents and PRMT5 inhibitors. Parallel development of MAT2A- and PRMT5-directed strategies has created a multilayered intervention framework extending from methyl-donor generation to methylation execution.

6 Products

6.1 Products for MTAP–MTA and Methyl-Donor Metabolism Research

Catalog #	Product Name/Description	Grade & Purity	Mechanism and Research Positioning
M1481592	MTAP Human Pre-designed siRNA Set A	—	Downregulates MTAP; used to establish MTAP-deficient models and validate MTA accumulation and PRMT5 dependency
Ab116212	Recombinant MTAP Antibody	Recombinant, ExactAb™, Validated, 0.5 mg/mL	Detects MTAP protein; used to verify MTAP expression and deficiency
D168979	5′-Deoxy-5′-(methylthio)adenosine	Moligand™, ≥95%	MTA metabolite used to model MTAP loss-associated MTA accumulation and PRMT5 regulation
M1498646	5'-Methylthioadenosine	Moligand™, 10 mM in DMSO	Used for cellular MTA treatment and MTA–PRMT5 dependency research
S192607	S-Adenosyl-L-methionine (SAM)	Moligand™, ≥98%	Methyl donor used in research on SAM/MTA balance and PRMT5-mediated methyltransferase reactions
S693949	S-adenosylmethionine	32 mM ± 2 mM	Used to investigate SAM supply and MAT2A–PRMT5 axis function
S139501	S-(5′-Adenosyl)-L-homocysteine (SAH)	Moligand™, ≥98%	Product of methyltransferase reactions; used to investigate SAM/SAH balance and cellular methylation status
M1480271	MAT2A Human Pre-designed siRNA Set A	—	Downregulates MAT2A; used to validate the effect of SAM supply on the survival of MTAP-deficient cells
M1480880	MAT2B Human Pre-designed siRNA Set A	—	Downregulates MAT2B; used to investigate MAT2 complex regulation and changes in SAM synthesis
S1433377	S-Adenosylmethionine synthetase (MAT)	Bioactive, Recombinant, ActiBioPure™, High Performance, EnzymoPure™, ≥90% (SDS-PAGE), ≥300 U/mg enzyme powder	Catalyzes SAM production; used in MAT activity and methyl-donor metabolism research
G1490325	GNMT Human Pre-designed siRNA Set A	—	Downregulates GNMT; used to investigate SAM consumption and cellular methyl-donor homeostasis
Ab105966	GNMT Mouse mAb	Carrier Free, ExactAb™, Validated, 0.5 mg/mL	Detects GNMT protein; used to investigate SAM consumption and methyl-group metabolism
rp184904	Recombinant Human Glycine N-methyltransferase/GNMT Protein	Carrier Free, ≥90% (SDS-PAGE), See COA	Used in GNMT enzymology and mechanisms associated with SAM consumption
A1486707	AHCY Human Pre-designed siRNA Set A	—	Downregulates AHCY; used to investigate the effect of SAH clearance on methyltransferase reactions
Ab126379	Recombinant SAHH Antibody	Recombinant, ExactAb™, Validated, See COA	Detects AHCY/SAHH; used in SAH metabolism and methylation-status research
rp188281	Recombinant Human Adenosylhomocysteinease/AHCY Protein	Carrier Free, His Tag, ≥90% (SDS-PAGE), See COA	Used in AHCY enzymology and research on SAH clearance mechanisms
EJ1514773	Human Adenosylhomocysteinase (AHCY) ELISA Kit	BioReagent	Quantifies AHCY; used in SAM/SAH metabolism research
A1481243	AMD1 Human Pre-designed siRNA Set A	—	Downregulates AMD1; used to investigate SAM diversion into polyamine synthesis and MTA production

6.2 Products for PRMT5 and MAT2A Functional Intervention

Catalog #	Product Name/Description	Grade & Purity	Mechanism and Research Positioning
P1471668	PRMT5 Human Pre-designed siRNA Set A	—	Downregulates PRMT5; used to validate PRMT5 dependency in MTAP-deficient cells
E276088	EPZ015866 (GSK591)	Moligand™, ≥98%	Inhibits PRMT5/MEP50 methyltransferase activity; used in SDMA and RNA splicing research
P414102	Pemrametostat (GSK3326595)	≥98%	Inhibits PRMT5; used in research on PRMT5 dependency, arginine methylation, and cell proliferation
P659371	PRMT5-IN-1 hydrochloride	≥99%	Inhibits PRMT5 catalytic activity; used in PRMT5 functional and pharmacological intervention research
M647103	MAT2A inhibitor 1	≥99%	Inhibits MAT2A and reduces SAM availability; used to investigate MTAP loss-associated metabolic vulnerability
M1494645	MAT2A inhibitor 2	Moligand™, 10 mM in DMSO	Used for cellular MAT2A inhibition and MAT2A–PRMT5 axis research
M275329	MS023	Moligand™, ≥98%	Inhibits type I PRMTs; used as a selectivity comparator for PRMT5 inhibition

6.3 Products for PRMT5 and Methylation Pathway Research

Catalog #	Product Name/Description	Grade & Purity	Detection Target/Mechanism and Research Positioning
Ab123105	Recombinant PRMT5 Antibody	Recombinant, ExactAb™, Validated, 0.8 mg/mL	Detects PRMT5 protein; used to verify expression levels and genetic or pharmacological intervention
EJ1514812	Human Protein Arginine N-methyltransferase 5 (PRMT5) ELISA Kit	BioReagent	Quantifies PRMT5; used to evaluate PRMT5 expression in biological samples
D1472832	DNMT1 Human Pre-designed siRNA Set A	—	Downregulates DNMT1; used to compare the effects of SAM availability on DNA methylation pathways
E1490171	EZH2 Human Pre-designed siRNA Set A	—	Downregulates EZH2; used to compare SAM-dependent histone methylation with the PRMT5 pathway
E647586	EZH2-IN-13	≥99%	Inhibits EZH2; used as a pharmacological control for SAM-dependent histone methyltransferase reactions
Ab112344	Recombinant KMT6/EZH2 Antibody	Recombinant, ExactAb™, Validated, 1.2 mg/mL	Detects EZH2 protein; used to investigate methylation pathways and intervention status

6.4 Products for Functional Validation of Cell Proliferation and Death

Catalog #	Product Name/Description	Grade & Purity	Detection Parameter and Research Positioning
P266304	Propidium iodide (PI)	≥98% (HPLC)	Used for DNA staining, cell-cycle analysis, and dead-cell detection
C1372489	Caspase 3/7 Activity Assay Kit	BioReagent	Detects Caspase-3/7 activity; used to evaluate executioner-caspase activation during apoptosis
L1373310	LDH Cytotoxicity Assay Kit with WST-8	BioReagent, Ready-to-use, for IP	Detects LDH release; used to evaluate cytotoxicity after pharmacological intervention
Z408507	Z-VAD-FMK	Moligand™, 10mM in DMSO	Broad-spectrum Caspase inhibitor used to determine whether cell death is Caspase-dependent

MTAP loss is not merely a defect in methionine salvage. Through MTA accumulation, it reduces the functional reserve of PRMT5 and increases cancer cell dependence on residual PRMT5 activity and MAT2A-mediated SAM supply. MTA-cooperative PRMT5 inhibition and MAT2A-directed intervention are translating this genomic deletion into a selectively exploitable therapeutic vulnerability.

References

[1] Kryukov GV, Wilson FH, Ruth JR, et al. MTAP deletion confers enhanced dependency on the PRMT5 arginine methyltransferase in cancer cells. Science. 2016;351(6278):1214–1218.

[2] Mavrakis KJ, McDonald ER 3rd, Schlabach MR, et al. Disordered methionine metabolism in MTAP/CDKN2A-deleted cancers leads to dependence on PRMT5. Science. 2016;351(6278):1208–1213.

[3] Marjon K, Cameron MJ, Quang P, et al. MTAP deletions in cancer create vulnerability to targeting of the MAT2A/PRMT5/RIOK1 axis. Cell Rep. 2016;15(3):574–587.

[4] Barekatain Y, Ackroyd JJ, Yan VC, et al. Homozygous MTAP deletion in primary human glioblastoma is not associated with elevation of methylthioadenosine. Nat Commun. 2021;12:4228.

[5] Kalev P, Hyer ML, Gross S, et al. MAT2A inhibition blocks the growth of MTAP-deleted cancer cells by reducing PRMT5-dependent mRNA splicing and inducing DNA damage. Cancer Cell. 2021;39(2):209–224.e11.

[6] Engstrom LD, Aranda R, Waters L, et al. MRTX1719 is an MTA-cooperative PRMT5 inhibitor that exhibits synthetic lethality in preclinical models and patients with MTAP-deleted cancer. Cancer Discov. 2023;13(11):2412–2431.

[7] Rodon J, Prenen H, Sacher A, et al. First-in-human study of AMG 193, an MTA-cooperative PRMT5 inhibitor, in patients with MTAP-deleted solid tumors: results from phase I dose exploration. Ann Oncol. 2024;35(12):1138–1147.

For more related articles, please see below:

[1] Methionine: Biological Roles and Key Points for Research Application

[2] Animal Modeling—Tumor Disease Models